DE602005006294D1 - Reinigungsverfahren für bakterielles cytolysin - Google Patents

Reinigungsverfahren für bakterielles cytolysin

Info

Publication number
DE602005006294D1
DE602005006294D1 DE602005006294T DE602005006294T DE602005006294D1 DE 602005006294 D1 DE602005006294 D1 DE 602005006294D1 DE 602005006294 T DE602005006294 T DE 602005006294T DE 602005006294 T DE602005006294 T DE 602005006294T DE 602005006294 D1 DE602005006294 D1 DE 602005006294D1
Authority
DE
Germany
Prior art keywords
bacterial cytolysin
salt
extract
cytolysin
cleaning procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005006294T
Other languages
English (en)
Other versions
DE602005006294T2 (de
Inventor
Ralph L Biemans
Carine Goraj
Emmanuel Mertens
A Vandercammen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE602005006294D1 publication Critical patent/DE602005006294D1/de
Application granted granted Critical
Publication of DE602005006294T2 publication Critical patent/DE602005006294T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
DE602005006294T 2004-09-22 2005-09-20 Reinigungsverfahren für bakterielles cytolysin Active DE602005006294T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0421083.7A GB0421083D0 (en) 2004-09-22 2004-09-22 Purification process
GB0421083 2004-09-22
PCT/EP2005/010258 WO2006032499A1 (en) 2004-09-22 2005-09-20 Purification process for bacterial cytolysin

Publications (2)

Publication Number Publication Date
DE602005006294D1 true DE602005006294D1 (de) 2008-06-05
DE602005006294T2 DE602005006294T2 (de) 2008-08-14

Family

ID=33397075

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005006294T Active DE602005006294T2 (de) 2004-09-22 2005-09-20 Reinigungsverfahren für bakterielles cytolysin

Country Status (15)

Country Link
US (1) US20070231876A1 (de)
EP (1) EP1791860B1 (de)
JP (1) JP4934591B2 (de)
AT (1) ATE393165T1 (de)
CA (1) CA2580113C (de)
CY (1) CY1107960T1 (de)
DE (1) DE602005006294T2 (de)
DK (1) DK1791860T3 (de)
ES (1) ES2304724T3 (de)
GB (1) GB0421083D0 (de)
HR (1) HRP20080242T3 (de)
PL (1) PL1791860T3 (de)
PT (1) PT1791860E (de)
SI (1) SI1791860T1 (de)
WO (1) WO2006032499A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541969A (en) 2003-03-13 2008-01-31 Glaxosmithkline Biolog Sa Purifying pneumolysin from Streptococcus pneumoniae in a single chromatographic step by binding it to a hydrophobic interaction column in the presence of detergent and high salt
CA2633772C (en) 2005-12-22 2015-09-15 Ralph Leon Biemans Pneumococcal polysaccharide conjugate vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2007281044A1 (en) * 2006-08-03 2008-02-07 Newcastle Innovation Limited Treatment and prevention of allergic airways diseases
BRPI0813307C1 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
WO2009094730A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
SG10201401516XA (en) 2009-09-03 2014-10-30 Pfizer Vaccines Llc Pcsk9 vaccine
WO2012127485A1 (en) * 2011-03-22 2012-09-27 Serum Institute Of India Ltd. A novel process for preparation of polysaccharides
EP2699587B1 (de) * 2011-04-22 2019-07-03 Wyeth LLC Zusammensetzungen im zusammenhang mit einem mutierten clostridium-difficile-toxin und verfahren dafür
MX339058B (es) 2011-05-17 2016-05-09 Glaxosmithkline Biolog Sa Vacuna contra streptococcus pneumoniae.
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP6335326B2 (ja) 2014-01-21 2018-05-30 ファイザー・インク コンジュゲート化莢膜糖類抗原を含む免疫原性組成物およびその使用
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
TWI684460B (zh) 2015-07-21 2020-02-11 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
GB201603029D0 (en) * 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
AR109290A1 (es) 2016-08-05 2018-11-14 Sk Chemicals Co Ltd Composición conjugada neumocócica multivalente de polisacárido y proteína
MX2019001342A (es) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Composicion de conjugado de proteina-polisacarido de neumococo multivalente.
JP7186166B2 (ja) 2016-12-30 2022-12-08 バックスサイト・インコーポレイテッド 非天然アミノ酸とのポリペプチド抗原接合体
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
RU2762723C2 (ru) 2017-01-20 2021-12-22 Пфайзер Инк. Иммуногенные композиции для применения в пневмококковых вакцинах
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102486891B1 (ko) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
EP3749358A4 (de) 2018-02-05 2022-04-20 Sanofi Pasteur, Inc. Polyvalente pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
AU2019256218A1 (en) 2018-04-18 2020-12-03 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
GB201807303D0 (en) * 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN114728050A (zh) 2019-07-31 2022-07-08 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
BR112022015796A2 (pt) 2020-02-21 2022-10-11 Pfizer Purificação de sacarídeos
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
US20220387613A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2023207315A1 (en) 2022-01-13 2024-06-27 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT58804A (en) * 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
DE4133707A1 (de) * 1991-10-11 1993-04-15 Behringwerke Ag Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung
US5652125A (en) * 1996-06-10 1997-07-29 Pharmacia S.P.A. Process for preparing daunorubicin
WO1999003884A2 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
NZ541969A (en) * 2003-03-13 2008-01-31 Glaxosmithkline Biolog Sa Purifying pneumolysin from Streptococcus pneumoniae in a single chromatographic step by binding it to a hydrophobic interaction column in the presence of detergent and high salt
JP4578067B2 (ja) * 2003-06-06 2010-11-10 宏 清水 局所医薬組成物

Also Published As

Publication number Publication date
PT1791860E (pt) 2008-05-20
CA2580113A1 (en) 2006-03-30
JP4934591B2 (ja) 2012-05-16
WO2006032499A1 (en) 2006-03-30
GB0421083D0 (en) 2004-10-27
SI1791860T1 (sl) 2008-08-31
DE602005006294T2 (de) 2008-08-14
JP2008513408A (ja) 2008-05-01
HRP20080242T3 (en) 2008-09-30
EP1791860B1 (de) 2008-04-23
DK1791860T3 (da) 2008-07-14
US20070231876A1 (en) 2007-10-04
ATE393165T1 (de) 2008-05-15
PL1791860T3 (pl) 2008-09-30
CY1107960T1 (el) 2013-09-04
ES2304724T3 (es) 2008-10-16
CA2580113C (en) 2018-01-16
EP1791860A1 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
DE602005006294D1 (de) Reinigungsverfahren für bakterielles cytolysin
CR8997A (es) Produccion de polipeptidos
CR8998A (es) PRODUCCION DE TNFR-Ig Y FUSION DE PROTEINA
CR8996A (es) PRODUCCION DE a-BETA
NZ597756A (en) Method for purifying recombinant adamts13 and other proteins and compositions thereof
UA92157C2 (ru) Способ продуцирования гормона роста
DE60031419D1 (de) Zusammensetzungen und verfahren für verbesserte zellkultur
ZA200510144B (en) Method for producing L-Lysine or L-Threonine using escherichia bacteria having attenuated malic enzyme acitivity
WO2006069610A3 (en) Process for the production of fine chemicals
WO2010080364A3 (en) Conditioned medium and methods of making the same
SG157346A1 (en) Improved purification of collagenases from clostridium histolyticum liquid culture
ATE324030T1 (de) Brassica-transformation durch teilchenbeschuss
NZ593239A (en) Fusion Collagenase in which affinity TAG is linked and method for producing the same
FR2931695B1 (fr) Procede d'extraction selective de proteines membranaires avec les calixarenes
DK1620549T3 (da) Fremgangsmåde til fremstilling af biologiske stoffer ved perfusionsdyrkning af suspenderede dyreceller
DE602005007476D1 (de) Verfahren zur reinigung von oozysten mittels enzymatischer verdauung von faeces
WO2007030674A3 (en) Use of nucleases to improve viability and enhance transgene expression in transfected cells
MXPA02010147A (es) Antagonistas cd40 para uso en el tratamiento de psoriasis y otras condiciones inflamatorias de la piel.
WO2004011637A3 (en) Modified adamts4 molecules and method of use thereof
CA2365626A1 (en) High production method of prenyl alcohol by microorganisms
GB2425312A (en) Method for cell surface display of target proteins using fadl of e coli
ATE415470T1 (de) Herstellungsverfahren für iturin a und dessen homologe
WO2008055671A3 (de) Verfahren zur aufreinigung wenigstens einer nachzuweisenden zielsubstanz
CA2758228C (en) Method for reducing methoxypyrazines in grapes and grape products
DE602007012053D1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: VANDERCAMMEN, A., RIXENSART, BE

Inventor name: GORAJ, CARINE, RIXENSART, BE

Inventor name: BIEMANS, RALPH L., RIXENSART, BE

Inventor name: MERTENS, EMMANUEL, RIXENSART, BE

8364 No opposition during term of opposition